Mercer Global Advisors
ATOS icon

Mercer Global Advisors’s Atossa Therapeutics ATOS Stock Holding History

Mercer Global Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28K Buy
+666
New +$3.04K ﹤0.01% 5692

Other funds holding ATOS

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
Aster Capital Management Dubai, United Arab Emirates $427M AUM 19.42% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mercer Global Advisors's ATOS Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Atossa Therapeutics (ATOS) in Q2 2026: 666 shares worth $1.28K. The stake represents ﹤0.01% of the portfolio and ranks #5692 among its holdings.

24 funds tracked by Wall St. Rank hold ATOS as of Q2 2026.

  • Mercer Global Advisors held 666 shares of Atossa Therapeutics worth $1.28K as of Q2 2026.
  • Atossa Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Atossa Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5692 holding.
  • 24 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.